Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to -$10.9 million.

  • Lucid Diagnostics' Cash from Operations fell 705.65% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.8 million, marking a year-over-year increase of 106.22%. This contributed to the annual value of -$44.1 million for FY2024, which is 3450.35% down from last year.
  • Lucid Diagnostics' Cash from Operations amounted to -$10.9 million in Q3 2025, which was down 705.65% from -$10.5 million recorded in Q2 2025.
  • Lucid Diagnostics' 5-year Cash from Operations high stood at -$4.3 million for Q4 2022, and its period low was -$13.3 million during Q2 2022.
  • Over the past 4 years, Lucid Diagnostics' median Cash from Operations value was -$10.0 million (recorded in 2023), while the average stood at -$9.4 million.
  • Within the past 5 years, the most significant YoY rise in Lucid Diagnostics' Cash from Operations was 4786.17% (2023), while the steepest drop was 13435.89% (2023).
  • Over the past 4 years, Lucid Diagnostics' Cash from Operations (Quarter) stood at -$4.3 million in 2022, then plummeted by 134.36% to -$10.0 million in 2023, then rose by 1.08% to -$9.9 million in 2024, then decreased by 10.35% to -$10.9 million in 2025.
  • Its last three reported values are -$10.9 million in Q3 2025, -$10.5 million for Q2 2025, and -$12.5 million during Q1 2025.